Market Overview

Spectrum Pharmaceuticals Announces FDA Approval of NDA for EVOMELA (melphalan) for Injection for use in two indications

Related SPPI
Your Cheat Sheet For Q1 Biotech Earnings
20 Biggest Mid-Day Losers For Wednesday

On March 10, 2016, Spectrum Pharmaceuticals, Inc. (the "Company") received notification from the U.S. Food and Drug Administration of the grant of approval of the Company's New Drug Application for EVOMELATM (melphalan) for Injection for use in two indications: 1) use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, and 2) for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

Posted-In: News FDA


Related Articles (SPPI)

View Comments and Join the Discussion!